In summary, glutamatergic dysregulation appears to be implicated in a cycle of toxicity in AD through several pathways, including microglia-mediated neuroinflammation, excitotoxicity, release and toxicity of Aβ, and tau release and tau propagation. This evidence concerns the gene MAPT and Alzheimer disease.